Patents by Inventor Peichao Lu
Peichao Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230052629Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.Type: ApplicationFiled: June 21, 2021Publication date: February 16, 2023Inventors: Christopher Becker, Xiaolin Li, Peichao Lu, Naomi Samadara Rajapaksa, David Charles Tully, Xiaojing Michael Wang, Qian Zhao
-
Publication number: 20220112189Abstract: The invention relates to compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for method for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of cryptosporidiosis by administering such a compound.Type: ApplicationFiled: October 12, 2021Publication date: April 14, 2022Inventors: Joseph Michael Young, Michael Robert Turner, Peichao Lu
-
Patent number: 11072610Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.Type: GrantFiled: September 12, 2019Date of Patent: July 27, 2021Assignee: Novartis AGInventors: Christopher Becker, Xiaolin Li, Peichao Lu, Naomi Samadara Rajapaksa, David Charles Tully, Xiaojing Michael Wang, Qian Zhao
-
Patent number: 10975078Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: GrantFiled: March 4, 2020Date of Patent: April 13, 2021Assignee: NOVARTIS AGInventors: Jiping Fu, Wooseok Han, Subramanian Karur, Peichao Lu, Keith Bruce Pfister, Joseph Michael Young
-
Publication number: 20200270265Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: ApplicationFiled: February 16, 2017Publication date: August 27, 2020Inventors: Jiping FU, Xianming JIN, Patrick LEE, Peichao LU, Joseph Michael YOUNG
-
Publication number: 20200270252Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: ApplicationFiled: March 4, 2020Publication date: August 27, 2020Inventors: Jiping FU, Wooseok HAN, Subramanian KARUR, Peichao LU, Keith Bruce PFISTER, Joseph Michael YOUNG
-
Publication number: 20200079772Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.Type: ApplicationFiled: September 12, 2019Publication date: March 12, 2020Inventors: Christopher Becker, Xiaolin Li, Peichao Lu, Naomi Samadara Rajapaksa, David Charles Tully, Xiaojing Michael Wang, Qian Zhao
-
Publication number: 20190300530Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: ApplicationFiled: April 12, 2019Publication date: October 3, 2019Inventors: Jiping FU, Wooseok HAN, Subramanian KARUR, Peichao LU, Keith Bruce PFISTER, Joseph Michael YOUNG
-
Patent number: 10301312Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: GrantFiled: April 27, 2018Date of Patent: May 28, 2019Assignee: Novartis AGInventors: Jiping Fu, Wooseok Han, Subramanian Karur, Peichao Lu, Keith Bruce Pfister, Joseph Michael Young
-
Patent number: 10160726Abstract: This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.Type: GrantFiled: August 3, 2015Date of Patent: December 25, 2018Assignee: Novartis AGInventors: Javier de Vicente Fidalgo, Haiying He, Cheng Hu, Zhigan Jiang, Xiaolin Li, Peichao Lu, Wosenu Mergo, Daniel Mutnick, Folkert Reck, Alexey Rivkin, Colin Keith Skepper, Xiaojing Michael Wang, Jianhua Xia, Yongjin Xu
-
Publication number: 20180312507Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: ApplicationFiled: April 27, 2018Publication date: November 1, 2018Inventors: Jiping FU, Wooseok HAN, Subramanian KARUR, Peichao LU, Keith Bruce PFISTER, Joseph Michael YOUNG
-
Patent number: 10093673Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: GrantFiled: October 12, 2017Date of Patent: October 9, 2018Assignee: Novartis AGInventors: Jiping Fu, Xianming Jin, Patrick Lee, Peichao Lu, Joseph Michael Young
-
Publication number: 20180030053Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: ApplicationFiled: October 12, 2017Publication date: February 1, 2018Inventors: Jiping FU, Xianming JIN, Patrick LEE, Peichao LU, Joseph Michael YOUNG
-
Patent number: 9845325Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: GrantFiled: February 16, 2017Date of Patent: December 19, 2017Assignee: Novartis AGInventors: Jiping Fu, Xianming Jin, Patrick Lee, Peichao Lu, Joseph Michael Young
-
Publication number: 20170240548Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.Type: ApplicationFiled: February 16, 2017Publication date: August 24, 2017Inventors: Jiping FU, Xianming JIN, Patrick LEE, Peichao LU, Joseph Michael YOUNG
-
Publication number: 20170217897Abstract: This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.Type: ApplicationFiled: August 3, 2015Publication date: August 3, 2017Inventors: Javier de Vicente FIDALGO, Haiying HE, Cheng HU, Zhigan JIANG, Xiaolin LI, Peichao LU, Wosenu MERGO, Daniel MUTNICK, Folkert RECK, Alexey RIVKIN, Colin Keith SKEPPER, Xiaojing Michael WANG, Jianhua XIA, Yongjin XU
-
Patent number: 9566312Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, and A-B are as defined herein, which are non-immunosuppressive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: GrantFiled: May 20, 2015Date of Patent: February 14, 2017Assignee: Novartis AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Publication number: 20150306172Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, and A-B are as defined herein, which are non-immunosuppressive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: ApplicationFiled: May 20, 2015Publication date: October 29, 2015Applicant: NOVARTIS AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Patent number: 9072696Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: GrantFiled: September 26, 2013Date of Patent: July 7, 2015Assignee: Novartis AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Publication number: 20140134132Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: ApplicationFiled: September 26, 2013Publication date: May 15, 2014Applicant: NOVARTIS AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
